.Pharmacolibrary.Drugs.ATC.L.L01XX73 .Pharmacolibrary.Drugs.ATC.L.L01XX73| name: | Sotorasib | |
| ATC code: | L01XX73 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 960 | mg |
| volume of distribution: | 211 | L |
| clearance: | 26.2 | L/h |
| other parameters in model implementation | ||
Sotorasib is an orally administered, small-molecule irreversible inhibitor of KRAS G12C, used for the treatment of non-small cell lung cancer (NSCLC) in patients with KRAS G12C mutation. It was approved by the FDA in 2021 and is actively in use for its labeled indication.
Pharmacokinetic parameters as reported in adult patients with advanced solid tumors, primarily non-small cell lung cancer, after oral administration.